Small Cell Lung Carcinoma
102
20
32
33
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
17 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.7%
16 terminated out of 102 trials
67.3%
-19.2% vs benchmark
9%
9 trials in Phase 3/4
52%
17 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 33 completed trials
Clinical Trials (102)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
A Study of LY4175408 in Participants With Advanced Cancer
An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
A Study of Hospital-at-Home for People Receiving Tarlatamab
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors